Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bone drug alendronate tested for sickle cell patients

NCT ID NCT06016634

Recruiting now Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study tests whether alendronate, a drug used for osteoporosis, can help adults with sickle cell disease who have bone damage (osteonecrosis). Thirty participants will take a weekly pill for 24 weeks. The main goals are to see if the treatment is feasible and safe, and to measure changes in pain and bone health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
alendronate (Fosamax), a bone-strengthening drug
What this could lead to
If it works, this could point toward a treatment to reduce bone pain and damage from osteonecrosis in sickle cell disease.
What could go wrong
This is a small, early feasibility study with only 30 participants and no placebo group. The drug may not improve symptoms or bone health, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AVASCULAR NECROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

avascular necrosis Legg-Calve-Perthes disease osteonecrosis sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AVASCULAR NECROSIS ISCHEMIC NECROSIS OSTEONECROSIS SICKLE CELL ANEMIA SICKLE CELL DISEASE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UC Davis Comprehensive Cancer Center

    RECRUITING

    Sacramento, California, 95817, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.